Omnicell (OMCL) Set to Announce Earnings on Thursday

Omnicell (NASDAQ:OMCL) is scheduled to release its earnings data before the market opens on Thursday, May 2nd. Analysts expect Omnicell to post earnings of ($0.08) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.22. Omnicell had a negative net margin of 1.78% and a positive return on equity of 3.43%. The company had revenue of $258.85 million for the quarter, compared to the consensus estimate of $256.00 million. On average, analysts expect Omnicell to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Omnicell Trading Down 3.5 %

NASDAQ:OMCL opened at $27.43 on Thursday. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -60.96 and a beta of 0.76. The company has a quick ratio of 2.22, a current ratio of 2.52 and a debt-to-equity ratio of 0.48. The company’s 50 day moving average price is $27.70 and its 200-day moving average price is $32.48. Omnicell has a 52 week low of $25.69 and a 52 week high of $77.14.

Analysts Set New Price Targets

Several research analysts have recently weighed in on OMCL shares. Barclays started coverage on Omnicell in a research note on Wednesday, January 3rd. They issued an “underweight” rating and a $33.00 price target for the company. Benchmark lowered their price objective on shares of Omnicell from $42.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, February 9th. Finally, Wells Fargo & Company dropped their price objective on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a report on Friday, February 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Omnicell currently has an average rating of “Hold” and a consensus price target of $42.20.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.